

# Ginisortamab Biosimilar - Research Grade

**Product Code:** ICH5244

**More Information**

**Species Reactivity:** Human

**Target:** GREM1

**Concentration:** >1mg/ml

**Isotype:** Human IgG4 - kappa

**Host:** CHO Cells

**product name H2:** Ginisortamab Biosimilar - Research Grade

**Sequence:** <https://www.imgt.org/mAb-DB/>

**Buffer:** ICH3002

**UniProt:** O60565

**Shipping Conditions:** Blue ice

**background:** ICH5244 is a research-grade biosimilar of ginisortamab, supplied as an unconjugated, non-therapeutic recombinant analog of the originator anti-Gremlin-1 (GREM1) antibody. It is a human IgG4-kappa built around the human GREM1 target (UniProt O60565) and is intended strictly for research use, not for human or veterinary application. The molecule is useful as a functional reference standard for investigators studying GREM1-directed antagonism: it supports binding and neutralisation assays, serves as a positive/isotype-matched control in BMP-pathway experiments, and provides a consistent tool for in-vitro and preclinical characterisation of GREM1 biology. Because it is manufactured as a research reagent, it is offered at low endotoxin (research grade below 1 EU/mg; ultra-low below 0.5 EU/mg) and in bulk milligram-to-gram quantities suitable for assay development, screening cascades, and comparability or bridging work. As a biosimilar

analog it recapitulates target recognition without being formulated or released as the clinical drug, making it appropriate for benchwork where reproducible, well-defined GREM1 engagement is required rather than therapeutic administration. Gremlin-1 (GREM1) is a secreted, cysteine-knot glycoprotein of the DAN family and a potent extracellular antagonist of bone morphogenetic proteins (BMPs), notably BMP-2, BMP-4 and BMP-7. By binding these ligands in the extracellular space, GREM1 prevents their engagement of BMP type I/II receptors, thereby restraining SMAD1/5/8 signalling and tuning the balance between BMP and TGF-beta pathway activity. GREM1 is essential in embryonic patterning, limb and kidney development, and it also modulates adult tissue homeostasis. Independently of BMP sequestration, GREM1 can act as an agonist ligand for VEGFR2, promoting angiogenic signalling. Aberrant GREM1 expression is implicated in fibrosis, and in the tumour microenvironment and cancer-associated fibroblasts, where elevated GREM1 supports stromal remodelling, proliferation and disease progression, motivating therapeutic neutralisation.

**Other names:** Cell proliferation-inducing gene 2 protein, Cysteine knot superfamily 1 BMP antagonist 1, DAN domain family member 2, Down-regulated in Mos-transformed cells protein, Increased in high glucose protein 2, IHG-2, Gremlin-1, CKTSF1B1, DAND2, DRM

**Specificity:** Detects human GREM1

**Purification Method:** This monoclonal antibody was purified using Protein A

**Formulation:** Sterile, preservative-free, solution in PBS. BSA and Azide free.

**Purity:** >95% by SDS-PAGE

**Endotoxin:**  $\leq 1.0$  EU/mg as determined by the LAL method

**Storage:** This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

**Applications:** Functional Assays

**Application Notes:** This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

**Use:** Products are for research use only. Not for use in diagnostic or therapeutic procedures.



**Delivery Time:** 4 weeks